Objective:

To enhance patient access to necessary medications and reduce costs associated with dry eye disease treatments.

Key Findings:

• Patient access to Vevye was previously hindered by prior authorizations and step therapy.
• The program offers Vevye at $59 per bottle, significantly lower than the market price.
• The initiative reduces the need for patients to try multiple medications before receiving the prescribed treatment.

Interpretation:

The Vevye Access for All program addresses critical barriers to medication access, potentially improving patient outcomes and reducing costs.

Limitations:

• The program's effectiveness may vary based on individual patient circumstances.
• Further expansion and partnerships with pharmacies are still in development.

Conclusion:

Harrow's initiatives reflect a commitment to improving patient access and affordability in the pharmaceutical industry.